<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interferons have been used for the treatment of many diseases because of their immunomodulatory, antiviral, antitumoral, and antiproliferative effects </plain></SENT>
<SENT sid="1" pm="."><plain>Systemic interferon alpha 2a (IFN-alpha 2a) is also efficacious in the management of <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) </plain></SENT>
<SENT sid="2" pm="."><plain>Many adverse cutaneous reactions related to IFN-alpha have been reported </plain></SENT>
<SENT sid="3" pm="."><plain>In the light of the current literature, we report here the first case of <z:e sem="disease" ids="C0032026" disease_type="Disease or Syndrome" abbrv="">Pityriasis rosea</z:e> (PR) that developed while receiving IFN-alpha 2a for BD </plain></SENT>
<SENT sid="4" pm="."><plain>However, since this is the first report on this association, further observations are needed to determine their clinical relevance </plain></SENT>
</text></document>